Home › Non-Small Cell Lung Cancer › Florida › Jacksonville
Non-Small Cell Lung Cancer clinical trials in Jacksonville, FL
39 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Jacksonville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
RecruitingPhase 3
- Cancer Specialists of North Florida - Riverside, Jacksonville
- Cancer Specialists of North Florida Southside, Jacksonville
- Cancer Specialists of North Florida - Northside, Jacksonville
- and 3 more
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
RecruitingPhase 2
- Mayo Clinic in Florida, Jacksonville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #78, Jacksonville
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RecruitingPhase 2/3
- Cancer Specialists of North Florida /ID# 277332, Jacksonville
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 1/2
- Research Site, Jacksonville
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RecruitingPhase 1
- Research Site, Jacksonville
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RecruitingPhase 1/2
- Mayo Clinic Hospital Jacksonville /ID# 275073, Jacksonville
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RecruitingPhase 3
- Mayo Clinic in Florida ( Site 0014), Jacksonville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Cancer Specialists of North Florida, Jacksonville
- Cancer Specialists of North Florida, Jacksonville
- Cancer Specialists of North Florida, Jacksonville
- and 4 more
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RecruitingPhase 1
- Research Site, Jacksonville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RecruitingObservational study
- Mayo Clinic Jacksonville, Jacksonville
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Baptist MD Anderson Cancer Center, Jacksonville
- Mayo Clinic, Jacksonville
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Mayo Clinic Jacksonville, Jacksonville
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RecruitingPhase 3
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center ( Site 0133), Jacksonville
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RecruitingPhase 2/3
- Baptist Medical Center Jacksonville, Jacksonville
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899, Jacksonville
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RecruitingPhase 3
- Cancer Specialists of North Florida, Jacksonville
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Research Site, Jacksonville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecruitingPhase 3
- Clinical Study Site, Jacksonville
- Clinical Study Site, Jacksonville Beach · 16 mi away
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RecruitingPhase 2/3
- 21st Century Oncology of Jacksonville - North Lee Street, Jacksonville
- Local Institution - 007-562-D, Jacksonville
- Local Institution - 007-562-E, Jacksonville
- and 5 more
A Study of KK2269 in Adult Participants With Solid Tumors
RecruitingPhase 1
- Mayo Clinic Jacksonville, Jacksonville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- University of Florida - Jacksonville, Jacksonville
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RecruitingPhase 1
- Mayo Jacksonville, Jacksonville
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Jacksonville
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
RecruitingPhase 1
- Mayo Clinic, Jacksonville
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
RecruitingPhase 1
- Mayo Clinic, Jacksonville
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RecruitingPhase 1
- Mayo Clinic - Florida, Jacksonville
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
RecruitingPhase 3
- Research Site, Jacksonville
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
RecruitingPhase 1/2
- Mayo Clinic in Florida, Jacksonville
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
RecruitingPhase 1/2
- Mayo Clinic in Florida, Jacksonville
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
RecruitingPhase 1/2
- Mayo Clinic - Florida, Jacksonville
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RecruitingPhase 1
- Mayo Clinic Jacksonville, Jacksonville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Mayo Clinic, Jacksonville
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RecruitingPhase 1
- Mayo Clinic Comprehensive Cancer Center, Jacksonville
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- Research Site, Jacksonville
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
- Mayo Clinic Jacksonville, Jacksonville
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
RecruitingObservational study
- Mayo Clinic in Florida, Jacksonville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Jacksonville
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RecruitingPhase 1/2
- Mayo Clinic, Jacksonville
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH56 studies
- Washington, DC55 studies
Other studies in Jacksonville
- Breast Cancer40 studies
- Cancer (all types)29 studies
- Metastatic Cancer28 studies
- Colorectal Cancer27 studies
- Prostate Cancer26 studies
- Obesity25 studies
- Heart Failure21 studies
- Pancreatic Cancer20 studies
- Overweight19 studies
- Multiple Myeloma18 studies
- Lung Cancer17 studies
- Stroke16 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.